<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36203683</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2296-2565</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in public health</Title><ISOAbbreviation>Front Public Health</ISOAbbreviation></Journal><ArticleTitle>Scars of COVID-19: A bibliometric analysis of post-COVID-19 fibrosis.</ArticleTitle><Pagination><StartPage>967829</StartPage><MedlinePgn>967829</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">967829</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fpubh.2022.967829</ELocationID><Abstract><AbstractText Label="BACKGROUND">The coronavirus disease 2019 (COVID-19) becomes a worldwide public health threat. Increasing evidence proves that COVID-19-induced acute injuries could be reversed by a couple of therapies. After that, post-COVID-19 fibrosis (PCF), a sequela of "Long COVID," earns rapidly emerging concerns. PCF is associated with deteriorative lung function and worse quality of life. But the process of PCF remains speculative. Therefore, we aim to conduct a bibliometric analysis to explore the overall structure, hotspots, and trend topics of PCF.</AbstractText><AbstractText Label="MATERIALS AND METHODS">A comprehensive search was performed in the Web of Science core database to collect literature on PCF. Search syntax included COVID-19 relevant terms: "COVID 19," "COVID-19 Virus Disease," "COVID-19 Virus Infection," "Coronavirus Disease-19," "2019 Novel Coronavirus Disease," "2019 Novel Coronavirus Infection," "SARS Coronavirus 2 Infection," "COVID-19 Pandemic," "Coronavirus," "2019-nCoV," and "SARS-CoV-2"; and fibrosis relevant terms: "Fibrosis," "Fibroses," and "Cirrhosis." Articles in English were included. Totally 1,088 publications were enrolled. Searching results were subsequentially exported and collected for the bibliometric analysis. National, organizational, and individual level data were analyzed and visualized through biblioshiny package in the R, VOSviewer software, the CiteSpace software, and the Graphical Clustering Toolkit (gCLUTO) software, respectively.</AbstractText><AbstractText Label="RESULTS">The intrinsic structure and development in the field of PCF were investigated in the present bibliometric analysis. The topmost keywords were "COVID-19" (occurrences, 636) surrounded by "SARS-CoV-2" (occurrences, 242), "coronavirus" (occurrences, 123), "fibrosis" (occurrences, 120), and "pneumonia" (occurrences, 94). The epidemiology, physiopathology, diagnosis, and therapy of PCF were extensively studied. After this, based on dynamic analysis of keywords, hot topics sharply changed from "Wuhan," "inflammation," and "cytokine storm" to "quality of life" and "infection" through burst detection; from "acute respiratory syndrome," "cystic-fibrosis" and "fibrosis" to "infection," "COVID-19," "quality-of-life" through thematic evolution; from "enzyme" to "post COVID." Similarly, co-cited references analysis showed that topics of references with most citations shift from "pulmonary pathology" (cluster 0) to "COVID-19 vaccination" (cluster 6). Additionally, the overview of contributors, impact, and collaboration was revealed. Summarily, the USA stood out as the most prolific, influential, and collaborative country. The Udice French Research University, Imperial College London, Harvard University, and the University of Washington represented the largest volume of publications, citations, <i>H</i>-index, and co-authorships, respectively. Dana Albon was the most productive and cited author with the strongest co-authorship link strength. <i>Journal of Cystic Fibrosis</i> topped the list of prolific and influential journals.</AbstractText><AbstractText Label="CONCLUSION">Outcomes gained from this study assisted professionals in better realizing PCF and would guide future practices. Epidemiology, pathogenesis, and therapeutics were study hotspots in the early phase of PCF research. As the spread of the COVID-19 pandemic and progress in this field, recent attention shifted to the quality of life of patients and post-COVID comorbidities. Nevertheless, COVID-19 relevant infection and vaccination were speculated to be research trends with current and future interest. International cooperation as well as in-depth laboratory experiments were encouraged to promote further explorations in the field of PCF.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Zhong, Zhou, Mei, Tang, Feng, He, Xu and Xing.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Han</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mei</LastName><ForeName>Shu-Ya</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Ri</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Jin-Hua</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Zheng-Yu</ForeName><Initials>ZY</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Qiao-Yi</ForeName><Initials>QY</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xing</LastName><ForeName>Shun-Peng</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Public Health</MedlineTA><NlmUniqueID>101616579</NlmUniqueID><ISSNLinking>2296-2565</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015706" MajorTopicYN="N">Bibliometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002921" MajorTopicYN="N">Cicatrix</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">etiology</Keyword><Keyword MajorTopicYN="N">fibrosis</Keyword><Keyword MajorTopicYN="N">hotspots and trends</Keyword><Keyword MajorTopicYN="N">therapy</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>7</Day><Hour>2</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36203683</ArticleId><ArticleId IdType="pmc">PMC9530282</ArticleId><ArticleId IdType="doi">10.3389/fpubh.2022.967829</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO . WHO Coronavirus (COVID-19) Dashboard. Available online at: https://covid19.who.int/ (accessed May 29, 2022).</Citation></Reference><Reference><Citation>Sun X, Wang T, Cai D, Hu Z, Chen J, Liao H, et al. . Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. (2020) 53:38&#x2013;42. 10.1016/j.cytogfr.2020.04.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2020.04.002</ArticleId><ArticleId IdType="pmc">PMC7182527</ArticleId><ArticleId IdType="pubmed">32360420</ArticleId></ArticleIdList></Reference><Reference><Citation>Vianello A, Guarnieri G, Braccioni F, Lococo S, Molena B, Cecchetto A, et al. . The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors. Clin Chem Lab Med. (2021). 10.1515/cclm-2021-1021</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2021-1021</ArticleId><ArticleId IdType="pubmed">34783228</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal A, Rochwerg B, Siemieniuk RA, Agoritsas T, Lamontagne F, Askie L, et al. . A living WHO guideline on drugs for COVID-19. BMJ. (2020) 370:m3379.</Citation><ArticleIdList><ArticleId IdType="pubmed">32887691</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalmers JD, Crichton ML, Goeminne PC, Cao B, Humbert M, Shteinberg M, et al. . Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. Eur Respir J. (2021) 57:2100048. 10.1183/13993003.00048-2021</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00048-2021</ArticleId><ArticleId IdType="pmc">PMC7947358</ArticleId><ArticleId IdType="pubmed">33692120</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambardar SR, Hightower SL, Huprikar NA, Chung KK, Singhal A, Collen JF. Post-COVID-19 pulmonary fibrosis: novel sequelae of the current pandemic. J Clin Med. (2021) 10:2452. 10.3390/jcm10112452</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10112452</ArticleId><ArticleId IdType="pmc">PMC8199255</ArticleId><ArticleId IdType="pubmed">34205928</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen Chan M, Benjamin P, Demigillo J, Pamela Demigillo MA, Xue J, Jesmajian S. Giraffe in the COVID-19 lung: pulmonary fibrosis limiting severity of the pneumothorax. Chest. (2021) 160:A393. 10.1016/j.chest.2021.07.393</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2021.07.393</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjot T, Webb GJ, Barritt ASt, Moon AM, Stamataki Z, Wong VW, et al. . COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol. (2021) 18:348&#x2013;64. 10.1038/s41575-021-00426-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-021-00426-4</ArticleId><ArticleId IdType="pmc">PMC7945972</ArticleId><ArticleId IdType="pubmed">33692570</ArticleId></ArticleIdList></Reference><Reference><Citation>George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Resp Med. (2020) 8:807&#x2013;15. 10.1016/S2213-2600(20)30225-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30225-3</ArticleId><ArticleId IdType="pmc">PMC7228727</ArticleId><ArticleId IdType="pubmed">32422178</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Dong C, Hu Y, Li C, Ren Q, Zhang X, et al. . Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: a longitudinal study. Radiology. (2020) 296:E55&#x2013;e64. 10.1148/radiol.2020200843</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2020200843</ArticleId><ArticleId IdType="pmc">PMC7233482</ArticleId><ArticleId IdType="pubmed">32191587</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo X, Jian W, Su Z, Chen M, Peng H, Peng P, et al. . Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J. (2020) 55:2001217. 10.1183/13993003.01217-2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01217-2020</ArticleId><ArticleId IdType="pmc">PMC7236826</ArticleId><ArticleId IdType="pubmed">32381497</ArticleId></ArticleIdList></Reference><Reference><Citation>Tale S, Ghosh S, Meitei SP, Kolli M, Garbhapu AK, Pudi S. Post-COVID-19 pneumonia pulmonary fibrosis. QJM. (2020) 113:837&#x2013;8. 10.1093/qjmed/hcaa255</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/hcaa255</ArticleId><ArticleId IdType="pmc">PMC7454835</ArticleId><ArticleId IdType="pubmed">32814978</ArticleId></ArticleIdList></Reference><Reference><Citation>Thille AW, Esteban A, Fern&#xe1;ndez-Segoviano P, Rodriguez JM, Aramburu JA, Vargas-Err&#xe1;zuriz P, et al. . Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: a prospective cohort study of clinical autopsies. Lancet Resp Med. (2013) 1:395&#x2013;401. 10.1016/S2213-2600(13)70053-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(13)70053-5</ArticleId><ArticleId IdType="pubmed">24429204</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold DT, Hamilton FW, Milne A, Morley AJ, Viner J, Attwood M, et al. . Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. (2021) 76:399&#x2013;401. 10.1136/thoraxjnl-2020-216086</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-216086</ArticleId><ArticleId IdType="pmc">PMC7716340</ArticleId><ArticleId IdType="pubmed">33273026</ArticleId></ArticleIdList></Reference><Reference><Citation>Michalski JE, Kurche JS, Schwartz DA. From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic? Transl Res. (2022) 241:13&#x2013;24. 10.1016/j.trsl.2021.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2021.09.001</ArticleId><ArticleId IdType="pmc">PMC8452088</ArticleId><ArticleId IdType="pubmed">34547499</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. (2020) 383:958&#x2013;68. 10.1056/NEJMra2005230</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2005230</ArticleId><ArticleId IdType="pubmed">32877584</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassiliou AG, Kotanidou A, Dimopoulou I, Orfanos SE. Endothelial damage in acute respiratory distress syndrome. Int J Mol Sci. (2020) 21:8793. 10.3390/ijms21228793</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21228793</ArticleId><ArticleId IdType="pmc">PMC7699909</ArticleId><ArticleId IdType="pubmed">33233715</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye C, Li H, Bao M, Zhuo R, Jiang G, Wang W. Alveolar macrophage&#x2014;derived exosomes modulate severity and outcome of acute lung injury. Aging. (2020) 12:6120&#x2013;8. 10.18632/aging.103010</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.103010</ArticleId><ArticleId IdType="pmc">PMC7185135</ArticleId><ArticleId IdType="pubmed">32259794</ArticleId></ArticleIdList></Reference><Reference><Citation>Botta C, Indrieri A, Garofalo E, Biamonte F, Bruni A, Pasqua P, et al. . COVID-19: high-JAKing of the inflammatory &#x201c;flight&#x201d; by ruxolitinib to avoid the cytokine storm. Front Oncol. (2020) 10:599502. 10.3389/fonc.2020.599502</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2020.599502</ArticleId><ArticleId IdType="pmc">PMC7819896</ArticleId><ArticleId IdType="pubmed">33489899</ArticleId></ArticleIdList></Reference><Reference><Citation>McElvaney OJ, McEvoy NL, McElvaney OF, Carroll TP, Murphy MP, Dunlea DM, et al. . Characterization of the inflammatory response to severe COVID-19 illness. Am J Respir Crit Care Med. (2020) 202:812&#x2013;21. 10.1164/rccm.202005-1583OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202005-1583OC</ArticleId><ArticleId IdType="pmc">PMC7491404</ArticleId><ArticleId IdType="pubmed">32584597</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkataraman T, Coleman CM, Frieman MB. Overactive epidermal growth factor receptor signaling leads to increased fibrosis after severe acute respiratory syndrome coronavirus infection. J Virol. (2017) 91:e00182-17. 10.1128/JVI.00182-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00182-17</ArticleId><ArticleId IdType="pmc">PMC5446658</ArticleId><ArticleId IdType="pubmed">28404843</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang FZ, Kream RM, Stefano GB. Long-term respiratory and neurological sequelae of COVID-19. Med Sci Monitor. (2020) 26:e928996-1. 10.12659/MSM.928996</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.928996</ArticleId><ArticleId IdType="pmc">PMC7643287</ArticleId><ArticleId IdType="pubmed">33177481</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. . Post-acute COVID-19 syndrome. Nat Med. (2021) 27:601&#x2013;15. 10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. . 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. (2021) 397:220&#x2013;32. 10.1016/S0140-6736(20)32656-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>George PM, Barratt SL, Condliffe R, Desai SR, Devaraj A, Forrest I, et al. . Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. (2020) 75:1009&#x2013;16. 10.1136/thoraxjnl-2020-215314</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-215314</ArticleId><ArticleId IdType="pubmed">32839287</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Q, Guan H, Sun Z, Huang L, Chen C, Ai T, et al. . Early CT features and temporal lung changes in COVID-19 pneumonia in Wuhan, China. Eur J Radiol. (2020) 128:109017. 10.1016/j.ejrad.2020.109017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejrad.2020.109017</ArticleId><ArticleId IdType="pmc">PMC7166310</ArticleId><ArticleId IdType="pubmed">32387924</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Wu J, Wang S, Li X, Zhou J, Huang B, et al. . Progression to fibrosing diffuse alveolar damage in a series of 30 minimally invasive autopsies with COVID-19 pneumonia in Wuhan, China. Histopathology. (2021) 78:542&#x2013;55. 10.1111/his.14249</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/his.14249</ArticleId><ArticleId IdType="pmc">PMC8848295</ArticleId><ArticleId IdType="pubmed">32926596</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y, Zhou R, Wu Q. Global research hotspots and research trends on idiopathic pulmonary fibrosis: a bibliometric and visualization analysis. Ann Palliat Med. (2021) 10:9057&#x2013;68. 10.21037/apm-21-1836</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/apm-21-1836</ArticleId><ArticleId IdType="pubmed">34455797</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Villar C, Garc&#xed;a-Santos JM. Bibliometric indicators to evaluate scientific activity. Radiolog&#xed;a (English Edition). (2021) 63:228&#x2013;35. 10.1016/j.rxeng.2021.01.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rxeng.2021.01.002</ArticleId><ArticleId IdType="pubmed">33593607</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MC, Nam S, Wang F, Zhu Y. Mapping scientific landscapes in UMLS research: a scientometric review. J Am Med Inform Assoc. (2020) 27:1612&#x2013;24. 10.1093/jamia/ocaa107</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa107</ArticleId><ArticleId IdType="pmc">PMC7647344</ArticleId><ArticleId IdType="pubmed">33059367</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhuri PK, Shukla AK, Abraham A. Industry 4.0: a bibliometric analysis and detailed overview. Eng Appl Artif Intell. (2019) 78:218&#x2013;35. 10.1016/j.engappai.2018.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.engappai.2018.11.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Russomanno K, Raiker R, Pakhchanian H, Deng M. Merkel cell carcinoma: a bibliometric analysis of the top 100 cited publications. Dermatol Surg. (2022) 48:22&#x2013;7. 10.1097/DSS.0000000000003251</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/DSS.0000000000003251</ArticleId><ArticleId IdType="pubmed">34608096</ArticleId></ArticleIdList></Reference><Reference><Citation>Aria M, Cuccurullo C. bibliometrix: An R-tool for comprehensive science mapping analysis. J Informetr. (2017) 11:959&#x2013;75. 10.1016/j.joi.2017.08.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.joi.2017.08.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C. Searching for intellectual turning points: progressive knowledge domain visualization. Proc Natl Acad Sci USA. (2004) 101(Suppl 1):5303&#x2013;10. 10.1073/pnas.0307513100</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0307513100</ArticleId><ArticleId IdType="pmc">PMC387312</ArticleId><ArticleId IdType="pubmed">14724295</ArticleId></ArticleIdList></Reference><Reference><Citation>Okhovati M, Arshadi H. COVID-19 research progress: Bibliometrics and visualization analysis. Med J Islam Repub Iran. (2021) 35:20. 10.47176/mjiri.35.20</Citation><ArticleIdList><ArticleId IdType="doi">10.47176/mjiri.35.20</ArticleId><ArticleId IdType="pmc">PMC8111634</ArticleId><ArticleId IdType="pubmed">33996671</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim TH, Kang JW. Research status quo in traditional Mongolian medicine: a bibliometric analysis on research documents in the web of science database. Evid Based Complement Alternat Med. (2021) 2021:5088129. 10.1155/2021/5088129</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/5088129</ArticleId><ArticleId IdType="pmc">PMC8727094</ArticleId><ArticleId IdType="pubmed">34992666</ArticleId></ArticleIdList></Reference><Reference><Citation>Da W, Tao Z, Meng Y, Wen K, Zhou S, Yang K, et al. . A 10-year bibliometric analysis of osteosarcoma and cure from 2010 to 2019. BMC Cancer. (2021) 21:115. 10.1186/s12885-021-07818-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12885-021-07818-4</ArticleId><ArticleId IdType="pmc">PMC7863524</ArticleId><ArticleId IdType="pubmed">33541299</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojo AS, Balogun SA, Williams OT, Ojo OS. Pulmonary fibrosis in COVID-19 survivors: predictive factors and risk reduction strategies. Pulm Med. (2020) 2020:6175964. 10.1155/2020/6175964</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/6175964</ArticleId><ArticleId IdType="pmc">PMC7439160</ArticleId><ArticleId IdType="pubmed">32850151</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald LT. Healing after COVID-19: are survivors at risk for pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol. (2021) 320:L257&#x2013;l65. 10.1152/ajplung.00238.2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.00238.2020</ArticleId><ArticleId IdType="pmc">PMC7900916</ArticleId><ArticleId IdType="pubmed">33355522</ArticleId></ArticleIdList></Reference><Reference><Citation>Spagnolo P, Balestro E, Aliberti S, Cocconcelli E, Biondini D, Casa GD, et al. . Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Resp Med. (2020) 8:750&#x2013;2. 10.1016/S2213-2600(20)30222-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30222-8</ArticleId><ArticleId IdType="pmc">PMC7228737</ArticleId><ArticleId IdType="pubmed">32422177</ArticleId></ArticleIdList></Reference><Reference><Citation>Scelfo C, Fontana M, Casalini E, Menzella F, Piro R, Zerbini A, et al. . A dangerous consequence of the recent pandemic: early lung fibrosis following COVID-19 pneumonia&#x2014;case reports. Therap Clin Risk Manag. (2020) 16:1039&#x2013;46. 10.2147/TCRM.S275779</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/TCRM.S275779</ArticleId><ArticleId IdType="pmc">PMC7605965</ArticleId><ArticleId IdType="pubmed">33154646</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabrera-Benitez NE, Laffey JG, Parotto M, Spieth PM, Villar J, Zhang H, et al. . Mechanical ventilation-associated lung fibrosis in acute respiratory distress syndrome: a significant contributor to poor outcome. Anesthesiology. (2014) 121:189&#x2013;98. 10.1097/ALN.0000000000000264</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0000000000000264</ArticleId><ArticleId IdType="pmc">PMC4991945</ArticleId><ArticleId IdType="pubmed">24732023</ArticleId></ArticleIdList></Reference><Reference><Citation>Seifirad S. Pirfenidone: a novel hypothetical treatment for COVID-19. Med Hypotheses. (2020) 144:110005. 10.1016/j.mehy.2020.110005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.110005</ArticleId><ArticleId IdType="pmc">PMC7297676</ArticleId><ArticleId IdType="pubmed">32575019</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogata H, Nakagawa T, Sakoda S, Ishimatsu A, Taguchi K, Kadowaki M, et al. . Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019. Respirol Case Rep. (2021) 9:e00744. 10.1002/rcr2.744</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rcr2.744</ArticleId><ArticleId IdType="pmc">PMC8008274</ArticleId><ArticleId IdType="pubmed">33815804</ArticleId></ArticleIdList></Reference><Reference><Citation>Dravid A, Kashiva R, Khan Z, Memon D, Kodre A, Potdar P, et al. . Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: a single center experience from Pune, Western India. Medicine (Baltimore). (2021) 100:e26705. 10.1097/MD.0000000000026705</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000026705</ArticleId><ArticleId IdType="pmc">PMC8294888</ArticleId><ArticleId IdType="pubmed">34398044</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Niu S, Guo B, Gao T, Wang L, Wang Y, et al. . Stem cell therapy for COVID-19, ARDS and pulmonary fibrosis. Cell Prolif. (2020) 53:e12939. 10.1111/cpr.12939</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cpr.12939</ArticleId><ArticleId IdType="pmc">PMC7645923</ArticleId><ArticleId IdType="pubmed">33098357</ArticleId></ArticleIdList></Reference><Reference><Citation>Song N, Wakimoto H, Rossignoli F, Bhere D, Ciccocioppo R, Chen KS, et al. . Mesenchymal stem cell immunomodulation: in pursuit of controlling COVID-19 related cytokine storm. Stem Cells. (2021) 39:707&#x2013;22. 10.1002/stem.3354</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.3354</ArticleId><ArticleId IdType="pmc">PMC8014246</ArticleId><ArticleId IdType="pubmed">33586320</ArticleId></ArticleIdList></Reference><Reference><Citation>Han W, Zhu M, Chen J, Zhang J, Zhu S, Li T, et al. . Lung transplantation for elderly patients with end-stage COVID-19 pneumonia. Ann Surg. (2020) 272:e33&#x2013;e4. 10.1097/SLA.0000000000003955</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000003955</ArticleId><ArticleId IdType="pmc">PMC7188057</ArticleId><ArticleId IdType="pubmed">32301803</ArticleId></ArticleIdList></Reference><Reference><Citation>Rumende CM, Susanto EC, Sitorus TP. The management of pulmonary fibrosis in COVID-19. Acta Med Indones. (2021) 53:233&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">34251354</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautret P, Million M, Jarrot PA, Camoin-Jau L, Colson P, Fenollar F, et al. . Natural history of COVID-19 and therapeutic options. Expert Rev Clin Immunol. (2020) 16:1159&#x2013;84. 10.1080/1744666X.2021.1847640</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2021.1847640</ArticleId><ArticleId IdType="pubmed">33356661</ArticleId></ArticleIdList></Reference><Reference><Citation>Li SF, Zhang YL, Guan ZQ, Li HL, Ye MD, Chen X, et al. . SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. Signal Transduct Target Ther. (2020) 5:1&#x2013;10. 10.1038/s41392-020-00334-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00334-0</ArticleId><ArticleId IdType="pmc">PMC7545816</ArticleId><ArticleId IdType="pubmed">33037188</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. (2020) 395:497&#x2013;506. 10.1016/S0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodr&#xed;guez L. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. (2020) 54:62&#x2013;75. 10.1016/j.cytogfr.2020.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2020.06.001</ArticleId><ArticleId IdType="pmc">PMC7265853</ArticleId><ArticleId IdType="pubmed">32513566</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheppard D. Transforming growth factor beta: a central modulator of pulmonary and airway inflammation and fibrosis. Proc Am Thorac Soc. (2006) 3:413&#x2013;7. 10.1513/pats.200601-008AW</Citation><ArticleIdList><ArticleId IdType="doi">10.1513/pats.200601-008AW</ArticleId><ArticleId IdType="pmc">PMC2658705</ArticleId><ArticleId IdType="pubmed">16799084</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbert JA, Deng Y, Hardelid P, Robinson E, Ren L, Moulding D, et al. . beta2-integrin LFA1 mediates airway damage following neutrophil transepithelial migration during respiratory syncytial virus infection. Eur Respir J. (2020) 56:1902216. 10.1183/13993003.02216-2019</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.02216-2019</ArticleId><ArticleId IdType="pmc">PMC7406857</ArticleId><ArticleId IdType="pubmed">32217648</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng Y, Herbert JA, Robinson E, Ren L, Smyth RL, Smith CM. Neutrophil-airway epithelial interactions result in increased epithelial damage and viral clearance during respiratory syncytial virus infection. J Virol. (2020) 94:e02161-19. 10.1128/JVI.02161-19</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02161-19</ArticleId><ArticleId IdType="pmc">PMC7307165</ArticleId><ArticleId IdType="pubmed">32295918</ArticleId></ArticleIdList></Reference><Reference><Citation>Berenguer J, Ryan P, Rodriguez-Bano J, Jarrin I, Carratala J, Pachon J, et al. . Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. Clin Microbiol Infect. (2020) 26:1525&#x2013;36. 10.1016/j.cmi.2020.07.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.07.024</ArticleId><ArticleId IdType="pmc">PMC7399713</ArticleId><ArticleId IdType="pubmed">32758659</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammerschmidt S, Kuhn H, Grasenack T, Gessner C, Wirtz H. Apoptosis and necrosis induced by cyclic mechanical stretching in alveolar type II cells. Am J Respir Cell Mol Biol. (2004) 30:396&#x2013;402. 10.1165/rcmb.2003-0136OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2003-0136OC</ArticleId><ArticleId IdType="pubmed">12959945</ArticleId></ArticleIdList></Reference><Reference><Citation>Senavirathna LK, Huang C, Yang X, Munteanu MC, Sathiaseelan R, Xu D, et al. . Hypoxia induces pulmonary fibroblast proliferation through NFAT signaling. Sci Rep. (2018) 8:2709. 10.1038/s41598-018-21073-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-21073-x</ArticleId><ArticleId IdType="pmc">PMC5807313</ArticleId><ArticleId IdType="pubmed">29426911</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendisch D, Dietrich O, Mari T, von Stillfried S, Ibarra IL, Mittermaier M, et al. . SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell. (2021) 184:6243-61.e27. 10.1016/j.cell.2021.11.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.11.033</ArticleId><ArticleId IdType="pmc">PMC8626230</ArticleId><ArticleId IdType="pubmed">34914922</ArticleId></ArticleIdList></Reference><Reference><Citation>Otoupalova E, Smith S, Cheng G, Thannickal VJ. Oxidative stress in pulmonary fibrosis. Compr Physiol. (2020) 10:509&#x2013;47. 10.1002/cphy.c190017</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cphy.c190017</ArticleId><ArticleId IdType="pubmed">32163196</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer MJ, White TA, Iijima K, Haak AJ, Ligresti G, Atkinson EJ, et al. . Cellular senescence mediates fibrotic pulmonary disease. Nat Commun. (2017) 8:14532. 10.1038/ncomms14532</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms14532</ArticleId><ArticleId IdType="pmc">PMC5331226</ArticleId><ArticleId IdType="pubmed">28230051</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrera J, Henke CA, Bitterman PB. Extracellular matrix as a driver of progressive fibrosis. J Clin Invest. (2018) 128:45&#x2013;53. 10.1172/JCI93557</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI93557</ArticleId><ArticleId IdType="pmc">PMC5749528</ArticleId><ArticleId IdType="pubmed">29293088</ArticleId></ArticleIdList></Reference><Reference><Citation>Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. . Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. (2011) 20:1727&#x2013;36. 10.1007/s11136-011-9903-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-011-9903-x</ArticleId><ArticleId IdType="pmc">PMC3220807</ArticleId><ArticleId IdType="pubmed">21479777</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechowicz K, Drozdzal S, Machaj F, Rosik J, Szostak B, Zegan-Baranska M, et al. . COVID-19: the potential treatment of pulmonary fibrosis associated with SARS-CoV-2 infection. J Clin Med. (2020) 9:1917. 10.3390/jcm9061917</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9061917</ArticleId><ArticleId IdType="pmc">PMC7356800</ArticleId><ArticleId IdType="pubmed">32575380</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. . An mRNA vaccine against SARS-CoV-2&#x2014;preliminary report. N Engl J Med. (2020) 383:1920&#x2013;31. 10.1056/NEJMoa2022483</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2022483</ArticleId><ArticleId IdType="pmc">PMC7377258</ArticleId><ArticleId IdType="pubmed">32663912</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Jung J, Cho H, Lee J, Go H, Lee JH, et al. . child with crescentic glomerulonephritis following SARS-CoV-2 mRNA (Pfizer-BioNTech) vaccination. Pediatr Nephrol. (2022). 10.1007/s00467-022-05681-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-022-05681-4</ArticleId><ArticleId IdType="pmc">PMC9296111</ArticleId><ArticleId IdType="pubmed">35854121</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J, Jain S, Sha J, Batra H, Ananthaswamy N, Kilgore PB, et al. . A bacteriophage-based, highly efficacious, needle- and adjuvant-free, mucosal COVID-19 vaccine. mBio. 2022:e0182222. 10.1101/2022.04.28.489809</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.04.28.489809</ArticleId><ArticleId IdType="pmc">PMC9426593</ArticleId><ArticleId IdType="pubmed">35900097</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng H, Liu H, Liu Z, Zhou X, Lu X, Yan Z, et al. . Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study. Human Vaccines Immunotherap. (2022) 2022:2090176. 10.1080/21645515.2022.2090176</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2090176</ArticleId><ArticleId IdType="pmc">PMC9621074</ArticleId><ArticleId IdType="pubmed">35878733</ArticleId></ArticleIdList></Reference><Reference><Citation>El Adam S, Zou M, Kim S, Henry B, Krajden M, Skowronski DM. SARS-CoV-2 mRNA vaccine effectiveness in health care workers by dosing interval and time since vaccination: test-negative design, British Columbia, Canada. Open Forum Infect Dis. (2022) 9:ofac178. 10.1093/ofid/ofac178</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac178</ArticleId><ArticleId IdType="pmc">PMC9047244</ArticleId><ArticleId IdType="pubmed">35531384</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabaan AA, Bakhrebah MA, Mutair AA, Alhumaid S, Al-Jishi JM, AlSihati J, et al. . Systematic review on pathophysiological complications in severe COVID-19 among the non-vaccinated and vaccinated population. Vaccines. (2022) 10:985. 10.3390/vaccines10070985</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10070985</ArticleId><ArticleId IdType="pmc">PMC9318201</ArticleId><ArticleId IdType="pubmed">35891149</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>